Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer

Data from first patient cohort provide human proof-of-concept and support continued dose escalation in patients with small cell lung cancer and large cell neuroendocrine carcinoma

Pharmacokinetic, dosimetry, and imaging data demonstrate selective tumor uptake and rapid clearance from blood and kidneys

ABD-147 tolerated at initial dose level, with early evidence of disease stabilization in advanced disease

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable precision radiopharmaceuticals for cancer, today announced initial clinical data from its ongoing Phase 1a trial of ABD-147 in patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) that support continued dose escalation. The data were presented in a poster session at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain.

ABD-147 is a targeted radiopharmaceutical biologic therapy designed to deliver Actinium-225 (²²⁵Ac), a potent alpha-emitting isotope, to solid tumors expressing delta-like ligand 3 (DLL3) with high affinity. DLL3 is expressed in approximately 85% of patients with SCLC, an intrinsically radiosensitive cancer.

“These data with ABD-147 validate the mechanistic promise of DLL3-targeted alpha radiotherapy and mark an important step toward a modality that could reshape SCLC treatment,” said Lisa Bodei, M.D., Ph.D., Nuclear Medicine Physician and Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center. “While early, at the first dose level, we observed selective tumor uptake, predicted biodistribution without evidence of alteration, and disease stabilization in advanced disease following platinum-based therapy. These findings support continued dose escalation and further evaluation in SCLC, where treatment options remain limited.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release